October 10, 2025

Eydenzelt Biosimilar Receives FDA Approval

The aflibercept biosimilar is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Retinal Physician

October 08, 2025

FDA Clears Gene Therapy Trial for GA

The Opti-GAIN phase 1/2 study of CTx001, which targets complement pathways in late-stage dry AMD, will evaluate safety and efficacy.

Retinal Physician

October 01, 2025

Navigating MacTel From Diagnosis to Therapy

Until recently, no treatment options were available for MacTel type 2. Standard management involved annual or semiannual monitoring to track vision changes and the onset of choroidal neovascularization, which, when present, could be treated with intravitreal anti-VEGF therapy. In March 2025, however, the FDA approved the first therapy for nonproliferative MacTel, revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals).

Retinal Physician

April 01, 2025

Clinical Trial Update April 2025

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

Retinal Physician

June 02, 2025

Geographic Atrophy: Early Detection and Patient Awareness Matters

Learn about the essential steps optometrists can take to support patients with geographic atrophy and preserve vision.

Optometric Management

September 22, 2025

Gift establishes UC Irvine’s Brunson Center for vision research

A $15 million gift launches UC Irvine’s Brunson Center for Vision Research, accelerating breakthroughs in treatments for blinding eye diseases.

UCI Health

April 01, 2018

Surgical Indications for Nonrhegmatogenous Retinal Detachment

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

November 01, 2019

Brimonidine Drug Delivery System for Geographic Atrophy

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician

January 01, 2023

Retinal Fluid Fluctuations in the Treatment of Neovascular AMD

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Retinal Physician